Delta-Radiomics Using Machine Learning Classifiers With Auxiliary Data Sets to Predict Disease Progression During Magnetic Resonance-Guided Radiotherapy in Adrenal Metastases.

PURPOSE: Adaptive radiotherapy accounts for interfractional anatomic changes. We hypothesize that changes in the gross tumor volumes identified during daily scans could be analyzed using delta-radiomics to predict disease progression events. We evaluated whether an auxiliary data set could improve prediction performance.

MATERIALS AND

METHODS

We analyzed 108 patients (n = 90 internal; n = 18 external) who received ablative radiotherapy. The internal data set included 42 patients with adrenal cancer, 23 patients with lung cancer, and 25 patients with pancreatic cancer, with the clinical end point of progression-free survival events. The median dose was 50 Gy, which was delivered over five fractions. The delta features are the ratio of the features of the last to first treatment fraction, F5/F1, and the concatenation of the first and last fraction features, F1||F5. Decision tree classifier with and without auxiliary data sets, and the external data set was used exclusively for independent testing of the final models.

RESULTS

During internal training, for the F1||F5 model, the inclusion of the lung data set increased our AUC receiver operator characteristic curve (ROC) from 0.53 ± 0.12 to 0.61 ± 0.11, whereas the pancreatic data set increased our AUC-ROC to 0.60 ± 0.14. For the F5/F1 model, the inclusion of the lung auxiliary data increased our AUC-ROC from 0.52 ± 0.13 to 0.65 ± 0.11, whereas it modestly changed by 0.62 ± 0.13 with the pancreas. During external testing, for the F5/F1 model, we reported an AUC-ROC of 0.60 with the lung auxiliary data and 0.43 with the pancreatic data. Also, for the F5||F1 model, we reported an AUC-ROC of 0.70 with the lung auxiliary and 0.60 with the pancreatic data.

CONCLUSION

Decision trees provided an explainable model on the external data set. The validation of our model on an external data set may be the first step to biologically adapted radiotherapy recognizing radiomics signals for potential recurrence.